Lung Cancer and the VA
Unfortunately lung cancer is on the rise. Early detection is key in patient outcomes. Veterans often find themselves facing difficult scenarios in search of answers and time is of the essence. Circulogene is helping to provide early detection and intervention of lung cancer with their non-invasive liquid biopsy technology. Our Veterans deserve the best care possible and they have access to this technology through testing in the VA.
Liquid biopsy LDX has been on the market for many years. Thousands of cancer patients have been tested. Circulogene is the only lung cancer company that provides the PD-L1 test. Results can be provided within a week to improve patient outcome and help with a treatment plan. Circulogene’s LungLifeAI technology allows for even better screening to determine the severity of pulmonary nodules by assessing a patient’s level of risk.
During a recent LinkedIn Live Circulogene CEO Mike Mullen Spoke with SDV President and CEO Dan Whisnant and SDV Director of Business Development David Mantica about lung cancer and the new technology available to offer early detection, sharing personal stories and examples of how lung cancer has affected people close to them.
Early detection of lung cancer and determining the severity is key. A process that used to take months now takes weeks or less. This is critical for better patient outcomes. SDV is proud to partner with Circulogene to provide the technology to save lives.
If you were unable to catch the live session, you can watch here anytime.